GSK Slims Portfolio With Sale of Rare Disease Gene Therapy Drugs GSK Slims Portfolio With Sale of Rare Disease Gene Therapy Drugs

GlaxoSmithKline is divesting its rare disease gene therapy drugs to Orchard Therapeutics, it said on Thursday, as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker ' s pharmaceuticals portfolio.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news